紫杉醇、多西紫杉醇和其他化疗药物相关的鼻前庭炎自然史：明尼苏达州癌症临床试验网络（MNCCTN）研究。

Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.

机构信息

Saint Luke's Cancer Specialists, 4321 Washington St. Ste 4000, Kansas City, MO, 64111, USA.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.

出版信息

Support Care Cancer. 2021 Nov;29(11):6253-6258. doi: 10.1007/s00520-021-06190-0. Epub 2021 Apr 13.

DOI:10.1007/s00520-021-06190-0

PMID:33851235

Abstract

PURPOSE

To describe the natural history of nasal vestibulitis in patients receiving taxane chemotherapy, including incidence, severity, and associated symptoms.

METHODS

Eligible patients with minimal or no baseline nasal symptoms were enrolled in this natural history study at initiation of a new chemotherapy regimen. Patients completed nasal symptom logs each time they received a chemotherapy dose. This manuscript reports upon the patients who received paclitaxel, docetaxel, or non-taxane non-bevacizumab chemotherapy. The proportions of patients within each cohort reporting any treatment-emergent nasal symptoms were estimated, with corresponding exact 95% confidence intervals. A cumulative incidence function was estimated within the chemotherapy cohorts to calculate the cumulative incidence rate of treatment-emergent nasal vestibulitis, treating death and disease progression as competing risks.

RESULTS

Of the 81 evaluable patients, nasal symptoms were reported by 76.5% (58.8%, 89.3%) receiving paclitaxel, 54.2% (32.8%, 74.5%) receiving docetaxel, and 47.8% (26.8%, 69.4%) receiving non-taxane and non-bevacizumab chemotherapy. Of the three pairwise chemotherapy group comparisons, both the tests comparing the cumulative incidence function between the paclitaxel and non-taxane non-bevacizumab chemotherapy cohorts and between the paclitaxel and docetaxel cohorts achieved statistical significance at the 5% level with a higher incidence of treatment-emergent nasal vestibulitis in the paclitaxel cohort in both comparisons (P = 0.026 and P = 0.035, respectively). These significant differences were retained in the cumulative incidence function regression analysis controlling for age, smoking history, allergies, and asthma. Most patients in the paclitaxel cohort reported nasal symptoms as moderate or severe (56%).

CONCLUSION

Patients receiving paclitaxel chemotherapy experience a high incidence of nasal symptoms.

摘要

目的

描述接受紫杉烷类化疗患者的鼻前庭炎自然史，包括发生率、严重程度和相关症状。

方法

在开始新的化疗方案时，纳入最小或无基线鼻症状的合格患者。患者每次接受化疗剂量时都会完成鼻腔症状日志。本手稿报告了接受紫杉醇、多西他赛或非紫杉烷非贝伐珠单抗化疗的患者。估计每个队列中报告任何治疗后出现的鼻腔症状的患者比例，并给出相应的精确 95%置信区间。在化疗队列中估计累积发生率函数，以计算治疗后出现的鼻前庭炎的累积发生率，将死亡和疾病进展视为竞争风险。

结果

在 81 名可评估患者中，58.8%（89.3%，95%置信区间）接受紫杉醇、32.8%（74.5%，95%置信区间）接受多西他赛和 26.8%（69.4%，95%置信区间）接受非紫杉烷和非贝伐珠单抗化疗的患者报告有鼻腔症状。在三个两两化疗组比较中，比较紫杉醇和非紫杉烷非贝伐珠单抗化疗组以及紫杉醇和多西他赛组之间累积发生率函数的两个检验均在 5%水平上达到统计学意义，紫杉醇组治疗后出现鼻前庭炎的发生率更高在这两种比较中（P = 0.026 和 P = 0.035）。在控制年龄、吸烟史、过敏和哮喘的累积发生率函数回归分析中保留了这些显著差异。紫杉醇组的大多数患者报告鼻腔症状为中度或重度（56%）。